Effects of the N-type Ca2+ channel blocker, Cilnidipine: Atelec®, on blood pressure levels and atherosclerosis indices in hypertensive patients with cerebrovascular disease.
Not Applicable
Recruiting
- Conditions
- Essential Hypertension
- Registration Number
- JPRN-UMIN000005523
- Lead Sponsor
- Ajinomoto Pharmaceuticals Co., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
Not provided
Exclusion Criteria
Pregnant or possibly pregnant patients.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method